Complete financial analysis of Mydecine Innovations Group Inc. (MYCOF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mydecine Innovations Group Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Times Guaranty Limited (TIMESGTY.BO) Income Statement Analysis – Financial Results
- LPKF Laser & Electronics SE (0ND2.L) Income Statement Analysis – Financial Results
- JS Corporation (194370.KS) Income Statement Analysis – Financial Results
- DD3 Acquisition Corp. II (DDMXU) Income Statement Analysis – Financial Results
- Chongqing Department Store Co.,Ltd. (600729.SS) Income Statement Analysis – Financial Results
Mydecine Innovations Group Inc. (MYCOF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.mydecine.com
About Mydecine Innovations Group Inc.
Mydecine Innovations Group Inc., a biotech and life sciences company, engages in the development and commercialization of drugs for treating mental health problems. It develops therapies for veterans, emergency medical service providers, post-traumatic stress disorder, and front-line workers; and operates Mindleap, a digital telehealth platform that provides access to mental health services, as well as psychedelic integration services, including psychedelic aftercare and wellness services. The company also engages in the drug discovery and builds nature-sourced psychedelic-assisted therapeutics, compounds, therapy protocols, and unique delivery systems. In addition, it operates hemp farm in Pottus, Texas. Mydecine Innovations Group Inc. has a partnership with Leiden University Medical Center; Royal Ottawa Mental Health Centre; LeadGen Labs to support psychedelic drug development; and Applied Pharmaceutical Innovation for drug development and clinical trial programs. The company was formerly known as NewLeaf Brands Inc. and changed its name to Mydecine Innovations Group Inc. in June 2020. Mydecine Innovations Group Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 7.49K | 58.49K | 125.57K | 207.66K | 0.00 | 0.00 | 84.00K | 84.00K | 49.00K | 0.00 |
| Cost of Revenue | 9.88K | 128.86K | 0.00 | 37.37K | 94.05K | 109.82K | 246.58K | 1.77M | 1.97M | 0.00 | 0.00 | 0.00 |
| Gross Profit | -9.88K | -128.86K | 7.49K | 21.12K | 31.52K | 97.83K | -246.58K | -1.77M | -1.88M | 84.00K | 49.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 100.00% | 36.11% | 25.10% | 47.11% | 0.00% | 0.00% | -2,243.43% | 100.00% | 100.00% | 0.00% |
| Research & Development | 1.08M | 3.59M | 3.96M | 1.29M | 0.00 | 0.00 | 0.00 | 0.00 | 1.05K | 0.00 | 0.00 | 0.00 |
| General & Administrative | 7.15M | 9.98M | 14.74M | 7.74M | 3.27M | 4.88M | 14.62M | 3.92M | 3.64M | 808.13K | 46.40K | 0.00 |
| Selling & Marketing | 1.15M | 0.00 | 0.00 | 2.33M | 71.51K | 730.22K | 693.83K | 259.75K | 41.10K | 14.00K | 0.00 | 0.00 |
| SG&A | 8.30M | 9.98M | 14.74M | 10.07M | 3.34M | 5.61M | 15.31M | 4.18M | 3.68M | 822.13K | 46.40K | 12.97 |
| Other Expenses | 0.00 | 2.82M | 3.99M | 292.02K | 149.99K | -4.54M | -97.92K | -4.28K | -2.95K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 19.64M | 16.39M | 22.69M | 11.65M | 3.49M | 5.90M | 15.70M | 4.19M | 3.81M | 929.46K | 73.26K | 41.06 |
| Cost & Expenses | 19.64M | 16.39M | 22.69M | 11.69M | 3.58M | 6.01M | 15.70M | 4.19M | 3.81M | 929.46K | 73.26K | 41.06 |
| Interest Income | 0.00 | 911.59 | 205.27 | 24.67 | 0.00 | 18.62K | 0.00 | 0.00 | 75.00 | 7.00 | 102.00 | 44.97 |
| Interest Expense | 1.30M | 911.59K | 205.27K | 182.87K | 68.31K | 69.95K | 6.90K | 47.42K | 107.13K | 30.02K | 32.88K | 0.00 |
| Depreciation & Amortization | 9.88K | 128.86K | 235.18K | 57.08K | 46.39K | 21.76K | 246.58K | 9.00K | 24.56K | 25.05K | 25.70K | 26.58 |
| EBITDA | -9.38M | -15.92M | -23.14M | -11.12M | -3.21M | -5.78M | -15.46M | -4.18M | -3.83M | -1.17M | 1.44K | -14.21 |
| EBITDA Ratio | 0.00% | 0.00% | -304,709.21% | -19,007.40% | -2,555.37% | -2,782.25% | 0.00% | 0.00% | -4,582.18% | -976.67% | 3.14% | 0.00% |
| Operating Income | -9.39M | -16.05M | -23.07M | -11.21M | -3.32M | -5.80M | -15.70M | 4.19M | 3.72M | 1.11M | 24.16K | -40.80 |
| Operating Income Ratio | 0.00% | 0.00% | -307,847.83% | -19,161.62% | -2,642.24% | -2,792.73% | 0.00% | 0.00% | 4,430.54% | 1,320.65% | 49.31% | 0.00% |
| Total Other Income/Expenses | -11.55M | -1.40M | -515.87K | -15.67M | -18.04M | -7.55M | -1.99M | -3.79M | -264.53K | -464.40K | -83.34K | -45.24 |
| Income Before Tax | -20.95M | -17.24M | -23.58M | -26.95M | -3.51M | -13.36M | -17.56M | -7.96M | -4.64M | -1.23M | -107.60K | -86.03 |
| Income Before Tax Ratio | 0.00% | 0.00% | -314,732.56% | -46,074.45% | -2,793.41% | -6,431.45% | 0.00% | 0.00% | -5,524.04% | -1,458.97% | -219.59% | 0.00% |
| Income Tax Expense | 0.00 | -5.39M | 5.14M | 608.14K | 219.51K | 69.95K | 6.90K | -306.19K | 107.13K | 30.02K | 32.88K | 0.00 |
| Net Income | -20.95M | -11.85M | -28.72M | -27.56M | -3.73M | -13.36M | -17.56M | -7.60M | -4.64M | -1.23M | -107.60K | -86.03 |
| Net Income Ratio | 0.00% | 0.00% | -383,287.92% | -47,114.19% | -2,968.22% | -6,431.45% | 0.00% | 0.00% | -5,524.04% | -1,458.97% | -219.59% | 0.00% |
| EPS | -0.68 | -1.37 | -6.13 | -12.12 | -8.37 | -122.07 | -311.45 | -243.37 | -191.20 | -58.15 | -44.08 | 0.00 |
| EPS Diluted | -0.68 | -1.37 | -6.13 | -12.12 | -8.37 | -122.07 | -311.15 | -243.37 | -191.20 | -58.15 | -44.08 | 0.00 |
| Weighted Avg Shares Out | 30.70M | 8.65M | 4.68M | 2.27M | 445.47K | 109.41K | 56.37K | 31.25K | 24.27K | 21.08K | 2.44K | 0.00 |
| Weighted Avg Shares Out (Dil) | 30.70M | 8.65M | 4.68M | 2.27M | 445.47K | 109.41K | 56.43K | 31.25K | 24.27K | 21.08K | 2.44K | 0.00 |
Mydecine Innovations Group Receives Two Notice of Allowances from USPTO for its MYCO-005 and MYCO-006 Family of Compounds
VANCOUVER, British Columbia, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NF0), a leading biotechnology company dedicated to transforming mental health and addiction treatment, proudly announces the issuance of two Notice...
Mydecine Innovations Group Announces Director Resignation
VANCOUVER, British Columbia, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE: 0NF0), a forefront biotechnology company dedicated to revolutionizing mental health and addiction treatment, announces that Neil Stevenson-Moore has resigned...
Mydecine Innovations Group Receives Notice of Allowance from USPTO for its MYCO-005 Compound
VANCOUVER, British Columbia, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA), a forefront biotechnology company dedicated to revolutionising mental health and addiction treatment, proudly announces the Company has received the...
Mydecine Announces Update Regarding the Special Access Program
DENVER, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis...
Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreements
VANCOUVER, British Columbia, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with...
Mydecine Provides Q4 2023 Business Update
VANCOUVER, British Columbia, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with...
Mydecine Innovations Group Announces Listing on the Canadian Securities Exchange and Delisting from the NEO
VANCOUVER, British Columbia, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NF0) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a...
Mydecine Innovations Group Announces Expected U.K. Dual Listing Admission Date
VANCOUVER, British Columbia, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a...
Mydecine Innovations Announces Amended Press Release Relating to the Closing of Prospectus Supplement Financing
VANCOUVER, British Columbia, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular...
Mydecine Innovations Announces Closing of Prospectus Supplement Financing
VANCOUVER, British Columbia, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a...
Source: https://incomestatements.info
Category: Stock Reports